But, the fixation on glycemic control as measured by glycosated hemoglobin (A1c) tests alone without considering the bigger issues, including quality-of-life issues, incidence of complications and other adverse events should be a big red flag to the medical establishment and especially the Food and Drug Administration that its time to consider issues besides glycemic control alone, something that